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Background: Pyrazolones are traditionally synthesized by the reaction of β-keto esters with hydrazine and its
derivatives. There are methods to synthesize β-keto esters from esters and aldehydes, but these methods have
main limitation in varying the substituents. Often, there are a number of methods such as acylation of enolates in
which a chelating effect has been employed to lock the enolate anion using lithium and magnesium salts;
however, these methods suffer from inconsistent yields in the case of aliphatic acylation. There are methods to
synthesize β-keto esters from ketones like caboxylation of ketone enolates using carbon dioxide and carbon
monoxide sources in the presence of palladium or transition metal catalysts. Currently, the most general and simple
method to synthesize β-keto ester is the reaction of dimethyl or ethyl carbonate with ketone in the presence of
strong bases which also requires long reaction time, use of excessive amount of reagent and inconsistent yield.
These factors lead us to develop a simple method to synthesize β-keto esters by changing the base and reagent.
Results: A series of β-keto esters were synthesized from ketones and ethyl chloroformate in the presence of base
which in turn are converted to pyrazolones and then subjected to cytotoxicity studies towards various cancer cell
lines and antimicrobial activity studies towards various bacterial and fungal strains.
Conclusion: The β-keto esters from ethyl chloroformate was successfully attempted, and the developed method is
simple, fast and applicable to the ketones having the alkyl halogens, protecting groups like Boc and Cbz that were
tolerated and proved to be useful in the synthesis of fused bicyclic and tricyclic pyrazolones efficiently using cyclic
ketones. Since this method is successful for different ketones, it can be useful for the synthesis of pharmaceutically
important pyrazolones also. The synthesized pyrazolones were subjected to antimicrobial, docking and cytotoxicity
assay against ACHN (human renal cell carcinoma), Panc-1 (human pancreatic adenocarcinoma) and HCT-116
(human colon cancer) cell line, and lead molecules have been identified. Some of the compounds are found to
have promising activity against different bacterial and fungal strains tested.
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Pyrazolones are important class of heterocyclic ring sys-
tems that have been used extensively in pharmaceutical
industry [1,2] due to their numerous applications as anal-
gesic, antipyretic, antiarthritic, uricosuric, anti-inflamma-
tory and antiphlogistic properties. Especially, a pyrazolone
derivative (edaravone) [3] acts as a radical scavenger to
interrupt the peroxidative chain reactions and membrane
disintegrations associated with ischemia [4-6]. Some of
the aryloxypyrazolone derivatives are useful in the treat-
ment of a variety of disorders caused by human immu-
nodeficiency virus and other genetic ailments caused by
retroviruses such as acquired immune deficiency syndro-
me [7]. In addition, these compounds are appropriate pre-
cursors for industrial preparation of herbicides [8], liquid
crystals [9,10], dyes [11], thermally stable polymers [12]
and colour photographical compounds [13]. Azadienophi-
les from the chemical oxidation of pyrazolones are acting
as suitable substrates for hetero Diels-Alder reactions [14].
Pyrazolones are traditionally synthesized by the reac-
tion of β-keto esters with hydrazine and its derivatives
[15-21]. There are a number of alternative methods to
synthesize pyrazolones which are documented in the lit-
erature [22-33] but tend to have serious drawbacks such
as step-intensive, carbon monoxide usage and sensitive
palladium catalysts. These factors revealed that using β-
keto esters as an intermediate is the broadest and most
efficient way to synthesize pyrazolones. There are methods
to synthesize β-keto esters from esters [34-37] (Claisen
condensation) and aldehydes [38,39], but these methods
have main limitation in varying the substituents. Often,
a number of methods such as acylation of enolates of
malonates [40,41], acylation of Meldrum's acid [42-45],
mixed malonate esters [46,47] and bistrimethylsilylmalo-
nate [48,49] have a chelating effect employed to lock the
enolate anion of malonate using lithium and magnesium
salts [50,51]; however, these methods suffer from incon-
sistent yields in the case of aliphatic acylation. There are
methods to synthesize β-keto esters from ketones like
caboxylation of ketone enolates [52-54] using carbon di-
oxide and carbon monoxide sources in the presence of
palladium or transition metal catalysts. Currently, the
most general and simple method to synthesize β-keto
ester is the reaction of dimethyl or ethyl carbonate with
ketone in the presence of strong bases [55,56]. This
method requires long reaction time, use of excessive
amount of reagent and inconsistent yield. These factors
lead us to develop a simple method to synthesize β-keto
esters by changing the base and reagent.
Methods
Antibacterial study
The newly synthesized pyrazoles for their antibac-
terial activity against Escherichia coli (ATTC-25922),Staphylococcus aureus (ATTC-25923), Pseudomonas
aeruginosa (ATTC-27853) and Klebsiella pneumonia
(recultured) bacterial strains by the disc diffusion method
[57,58]. The discs measuring 6.25 mm in diameter were
punched from Whatman No. 1 filter paper (GE Health-
care, Little Chalfont, UK). Batches of 100 discs were dis-
pensed to each screw-capped bottle and sterilized by dry
heat at 140°C for an hour. The test compounds were pre-
pared with different concentrations using DMF. One mil-
liliter containing 100 times the amount of chemical in
each disc was added to each bottle, which contains 100
discs. The discs of each concentration were placed in trip-
licate in a nutrient agar medium separately seeded with
fresh bacteria. The incubation was carried out at 37°C for
24 h. Solvent and growth controls were kept, and the
zones of inhibition and minimum inhibitory concen-
trations (MIC) were noted. Results of these studies
were given in Table 1 and compared with the stan-
dard ciprofloxacin.
Antifungal activity
Newly synthesized pyrazoles were screened for their an-
tifungal activity against Aspergillus flavus (NCIM no.
524), Aspergillus fumigates (NCIM no. 902), Penicillium
marneffei (recultured) and Trichophyton mentagrophytes
(recultured) in dimethylsulfoxide (DMSO) by the serial
plate dilution method [34-36]. Sabouraud agar media
was prepared by dissolving peptone (1 g), D-glucose
(4 g) and agar (2 g) in distilled water (100 mL), and the
pH was adjusted to 5.7. Normal saline was used to make
a suspension of spores of fungal strain for lawning. A
loopful of particular fungal strain was transferred to
3 mL of saline to get a suspension of corresponding spe-
cies. Agar media of 20 mL was poured into each Petri
dish. An excess of suspension was decanted, and the
plates were dried by placing them in an incubator at
37°C for 1 h. Using an agar, punch wells were made on
these seeded agar plates, and 10 to 50 μg/mL of the test
compounds in DMSO were added into each labelled
well. A control was also prepared for plates in the
same way using solvent DMSO. The Petri dishes were
prepared in triplicate and maintained at 37°C for 3 to
4 days. Antifungal activity was determined by measur-
ing the inhibition zone. The results of these studies
were given in Table 2 and compared with the stan-
dard ciclopiroxolamine.
Docking studies
All the synthesized compounds 1 to 26 have been
subjected to the docking studies against ACHN (human
renal cell carcinoma), Panc-1 (human pancreatic adeno-
carcinoma) and HCT-116 (human colon cancer) and
then subjected to WST-1 cytotoxicity assay. Based on
the crystal structures of the target proteins and high-
Table 2 Antifungal activities of the newly synthesized
compounds
Trichophyton Penicillium A. flavus A. fumigates
Compound
number
1 25 (6.25) 23 (6.25) 26 (6.25) 27 (6.25)
2 24 (6.25) 25 (6.25) 24 (6.25) 26 (6.25)
3 29 (6.25) 26 (6.25) 27 (6.25) 28 (6.25)
4 21 (6.25) 22 (6.25) 26 (6.25) 22 (6.25)
5 16 (12.5) 17 (12.5) 12 (12.5) 14 (12.5)
6 17 (12.5) 17 (12.5) 11 (12.5) 15 (12.5)
7 24 (12.5) 21 (12.5) 21 (12.5) 20 (12.5)
8 26 (12.5) 24 (12.5) 27 (12.5) 23 (12.5)
9 27 (12.5) 25 (12.5) 28 (12.5) 22 (12.5)
10 20 (6.25) 22 (6.25) 17 (6.25) 22 (6.25)
11 21 (6.25) 21 (6.25) 23 (6.25) 21 (6.25)
13 22 (12.5) 25 (12.5) 27 (12.5) 23 (12.5)
14 30 (12.5) 22 (12.5) 26 (12.5) 24 (12.5)
15 26 (12.5) 23 (12.5) 27 (12.5) 23 (12.5)
17 31 (12.5) 25 (12.5) 28 (12.5) 23 (12.5)
19 25 (6.25) 24 (6.25) 27 (6.25) 24 (6.25)
20 28 (12.5) 29 (12.5) 25 (12.5) 25 (12.5)
21 31 (12.5) 28 (12.5) 27 (12.5) 24 (12.5)
23 29 (12.5) 27 (12.5) 26 (12.5) 21 (12.5)
24 23 (12.5) 26 (12.5) 23 (12.5) 25 (12.5)
25 21 (6.25) 20 (6.25) 21 (6.25) 23 (6.25)
26 25 (12.5) 22 (12.5) 27 (12.5) 28 (12.5)
Standard 27 (3.125) 23 (6.25) 27 (3.125) 26 (6.25)
Zone of inhibition (mm), MIC (μg/mL) given in parenthesis and
ciclopiroxolamine as standard.
Table 1 Antibacterial activity of the newly synthesized
compounds
S. aureus E. coli P. aeruginosa K. pneumonia
Compound
number
1 21 (6.25) 17 (6.25) 18 (6.25) 20 (6.25)
2 20 (6.25) 18 (6.25) 19 (6.25) 21 (6.25)
3 23 (6.25) 19 (6.25) 20 (6.25) 22 (6.25)
4 20 (6.25) 17 (6.25) 18 (6.25) 19 (6.25)
5 16 (100) 17 (100) 12 (100) 14 (100)
6 17 (100) 17 (100) 11 (100) 15 (100)
7 26 (12.5) 23 (12.5) 21 (12.5) 20 (12.5)
8 19 (100) 23 (100) 22 (100) 16 (100)
9 26 (6.25) 23 (6.25) 21 (6.25) 20 (6.25)
10 22 (6.25) 18 (6.25) 19 (6.25) 21 (6.25)
11 17 (6.25) 21 (6.25) 20 (6.25) 21 (6.25)
13 28 (12.5) 22 (12.5) 25 (12.5) 23 (12.5)
14 29 (12.5) 25 (12.5) 22 (12.5) 21 (12.5)
15 23 (6.25) 20 (6.25) 21 (6.25) 22 (6.25)
17 31 (12.5) 25 (12.5) 27 (12.5) 20 (12.5)
19 18 (6.25) 19 (6.25) 22 (6.25) 20 (6.25)
20 24 (6.25) 25 (6.25) 26 (6.25) 26 (6.25)
21 30 (12.5) 24 (12.5) 25 (12.5) 22 (12.5)
23 24 (12.5) 27 (12.5) 24 (12.5) 23 (12.5)
24 16 (100) 17 (100) 12 (100) 14 (100)
25 21 (12.5) 24 (12.5) 26 (12.5) 22 (12.5)
26 21 (6.25) 23 (6.25) 22 (6.25) 20 (6.25)
Ciprofloxacin 23 (6.25) 32 (6.25) 28 (6.25) 24 (6.25)
Zone of inhibition (mm); MIC (μg/mL) given in parenthesis.
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Gemdock methods were used. These phases include
target protein structure analysis, ligand optimization, mo-
lecular docking and post-docking analysis. The macro-
and small-molecule optimization phase involved in editing
the structural coordinates of the target protein and com-
pounds. The third phase was molecular docking method
to identify potential leads for the target protein; then, the
fourth phase was post-docking analysis to identify best
conformation of ligand molecule. In the present study, the
coordinates of three cancer target proteins were selected
and obtained from the Protein Data Bank (PDB) [59]. The
PDB entry 1SVC (pancreatic cancer), 3B8Q (renal cancer)
and 4FLH (colon cancer) were selected for structural
analysis based on its high-resolution crystallographic
structure. For docking studies, the PDB coordinates of
obtained target proteins were edited by removing the co-
crystallized ligand molecule. The crystallographic water
molecules were eliminated from the atomic coordinate
file, and the polar hydrogen atoms and Kollman united
charges were added to each target protein, followed bystructure optimization and refinement using spdbv viewer
[60]. The synthesized chemical compound structures were
sketched with the help of ChemSketch [61]. A three-
dimensional (3D) conversion and geometry optimization
of all the compounds were performed using chimera [62]
for flexible conformations of the compounds during the
docking. To study the detailed intermolecular interactions
between the target protein and the ligand molecule, auto-
mated docking program iGEMDOCK (a generic evolu-
tionary method for molecular DOCKing) software
was used [63]. iGEMDOCK integrated the virtual screen-
ing, molecular docking, post-screening analysis and
visualization steps. We selected nuclear factor kappa b
(NF-κb), vascular endothelial growth factor receptor-2
and human phosphoinositide 3-kinase (PI3K-gamma)
(PDB ID: 1SVC, 3B8Q and 4FLH, respectively) as target
proteins to carry out the docking analysis of our synthe-
sized compounds. The 3D coordinates of each therapeutic
target protein were implemented through the GEMDOCK
graphical environment interface. Then, the default option
Table 3 Docking results of synthesized compounds in the
binding site of nuclear factor kappa b
Compound number Total energy Z score VDW
1 −74.15 −73.1 −73.15
2 −66.2304 −70.6 −56.7448
3 −78.2994 −90.8 −65.8385
4 −42.783 −45.93 −68.7026
5 −50.5602 −54.9 −50.366
6 −88.1508 −110.2 −70.312
7 −32.2859 −40.6 −55.3665
8 −49.5672 −50.8 −56.3479
9 −62.3895 −62.4 −50.3603
10 −74.4438 −72.3 −70.4519
11 −90.4298 −117.4 −80.5608
12 −83.3089 −90.4 −67.7796
13 −42.6816 −50.3 −60.7439
14 −91.9971 −119.9 −74.1695
15 −35.7564 −46.7 −68.4413
16 −72.932 −69.9 −60.4764
17 −60.4516 −60.2 −60.3893
18 −34.3128 −101.7 −53.5055
19 −41.0148 −50.9 −63.3827
20 −35.2375 −40.6 −87.3575
21 −79.2554 −85.2 −51.5586
22 −39.9575 −42.3 −67.6976
23 −32.1991 −42.3 −63.8354
24 −58.4277 −60.9 −67.0823
25 −58.424 −60.9 −53.7606
26 −30.0129 −44.6 −44.8782
Table 4 Docking results of synthesized compounds in the
binding site of vascular endothelial growth factor
receptor-2
Compound number Total energy Z score VDW
1 −75.0934 −72.2 −79.4166
2 −78.2062 −75.1 −69.6532
3 −70.5653 −95.6 −68.46
4 −78.7892 −72.3 −63.191
5 −65.564 −78.9 −59.3404
6 −86.6543 −105.7 −80.5888
7 −71.8927 −63.17 −59.0905
8 −95.9923 −120.5 −94.7849
9 −79.948 −71.9 −56.0692
10 −73.5766 −80 −86.6021
11 −72.3245 −73.6 −73.1902
12 −75.4277 −72.2 −70.7142
13 −85.3265 −94.6 −54.4274
14 −75.329 −75.3 −71.2839
15 −80.914 −75.1 −73.6739
16 −75.3033 −91.5 −63.0176
17 −68.7853 −74.3 −69.6841
18 −104.9856 −125.5 −105.697
19 −92.6464 −115.2 −87.8944
20 −74.3443 76.7 −70.902
21 −62.3597 −73.3 −50.6291
22 −60.2348 −78.2 −65.3015
23 −77.191 −75.6 −63.8723
24 −82.723 −77.2 −68.4238
25 −80.73 −75 −56.4072
26 −75.093 −104.3 −48.6469
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compounds. Before docking, the output path was set.
GEMDOCK default parameters included the population
size (n = 200), generation (g = 70) and number of solu-
tions (s = 10) to compute the probable binding conform-
ation of synthesized compounds. Then, the docking run
was started using GEMDOCK scoring function. After
docking, the individual binding conformation of each lig-
and was observed, and their binding affinity with the tar-
get proteins was analyzed. The best binding pose and
binding energy of each ligand was selected. In the post-
docking analysis, van der Waals score, Z score and the de-
tails of interacted residues were saved in output folder.
Protein-ligand binding site was analyzed and visualized
using PyMOL [64]. The three-dimensional structures of
NF-κb, vascular endothelial growth factor receptor-2 and
human phosphoinositide 3-kinase are analyzed, and syn-
thesized compounds 1 to 26 are optimized to have min-
imal potential energy using chimera. After minimization,
all the ligands are docked into each target protein to study
the molecular basis of interaction and binding affinity ofall the synthesized compounds. From the docking analysis,
we listed best conformers based on total energy, Z score
and van der Waals score (VDW) for each ligand molecule
(Tables 3,4,5). The best docking poses for each ligand mol-
ecule into each target protein are determined, and the one
having the lowest binding energy among the 20 different
poses generated. The lower energy scores represent better
protein-ligand binding affinity compared to higher energy
values.
Cytotoxicity studies
The compounds 1 to 26 have been subjected to cycto-
toxicity studies. Towards this, a panel of three cancer
cells representing multiple cancers of clinical relevance
were obtained from American Type Culture Collection
(ATCC), namely ACHN (human renal cell carcinoma),
Panc-1 (human pancreatic adenocarcinoma) and HCT-
116 (human colon cancer). Cells were maintained in
Dulbecco's modified Eagle's medium (DMEM) medium
containing 10% heat-inactivated fetal bovine serum and
Table 5 Docking results of synthesized compounds in the
binding site of phosphoinositide 3-kinase
Compound number Total energy Z score VDW
1 −119.541 −122.5 −78.0144
2 −67.4663 68.3 −53.8734
3 −105.3452 −90.9 −68.1224
4 −75.0481 −75 −70.3258
5 −77.1818 −77.2 −61.47
6 −101.23 −105.1 −55.6405
7 −96.8291 −110.9 −54.3328
8 −92.0488 −92 −61.893
9 −75.3184 −75.3 −62.0764
10 −119.421 −120.5 −76.7195
11 92.8443 −92.3 −62.324
12 −83.9072 −83.9 −85.1019
13 −80.5887 −80.6 −66.5004
14 −107.157 −102.2 −62.1177
15 −76.9716 −77 −70.2072
16 −94.8943 −106.4 −52.3224
17 −90.9786 −91.4 −66.5817
18 −110.067 −91 −80.4918
19 −83.2508 −83.3 −54.2574
20 −76.3532 −76.3 −86.3532
21 −82.2975 −82.3 −54.9572
22 −74.2083 −74.2 −71.0281
23 −81.0895 −81.1 −63.5472
24 −76.2358 −76.2 −58.7925
25 −67.4663 −67.5 −49.4389
26 −80.9917 −81.1 −48.6582
Table 6 Cytotoxic activity of the newly synthesized













1 10 −75 −7 −138
2 10 −64 5 1
3 10 −78 0 −16
4 10 −10 20 −12
5 10 −20 −3 6
6 10 −101 −25 −116
7 10 14 −16 −115
8 10 −15 −31 −107
9 10 −56 19 8
10 10 −75 −7 −138
11 10 −117 7 −107
12 10 −89 13 −70
13 10 −14 3 5
14 10 −118 −19 −123
15 10 12 5 17
16 10 −71 −10 −112
17 10 −51 4 −102
18 10 4 −41 −128
19 10 −10 −26 −80
20 10 71 73 79
21 10 −80 −5 −20
23 10 12 −7 −6
24 10 6 2 −103
25 10 −45 −18 −64
26 10 −7 −12 1
Tannase 10 17.3 12.4 9.7
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mically, growing cells were plated at a density of 5 × 103
cells/well in a 96-well tissue culture grade micro-plate
and allowed to recover overnight. The cells were chal-
lenged with varying concentrations of compounds for
48 h. Control cells received standard media containing
dimethylsulfoxide vehicle at a concentration of 0.2%.
After 48 h of incubation, cell toxicity was determined by
the Cell Counting Kit-8 (CCK-8) reagent (Dojindo Mo-
lecular Technologies, Inc., Kumamoto, Japan); (WST-1
[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)]-2H-tetrazolium, monosodium salt assay).
In accordance with the manufacturer's instructions [36],
5 μL/well CCK-8 reagent was added, and plates were incu-
bated for 2 h. Cytotoxicity of all the compounds have been
determined by measuring the absorbance on Tecan
Sapphire multi-fluorescence micro-plate reader (Tecan
GmbH, Crailsheim, Germany) at a wavelength of 450 nm
corrected to 650 nm and normalized to controls. Each in-
dependent experiment was performed thrice and tabu-
lated in Table 6.Results and discussion
In continuation of our interest towards the synthesis of
β-keto esters and pyrazolones [65-67], we made an at-
tempt to synthesize β-keto esters from ethyl chloro-
formate in the presence of base which in turn are
converted into pyrazolones in situ by the addition of ei-
ther hydrazine or its derivatives, since we hypothesized
that an enolate may react cleanly with highly electro-
philic ethyl chloroformate to give β-keto esters. We tes-
ted our hypothesis in the synthesis of representative
compound 12 by varying the solvents as well as bases
(Scheme 1). The effects of base and solvent on the yield
of 12 have been summarized and are given in Table 7.
The formation of β-keto ester was found to be in bet-
ter yield when LiHMDS was used as a base. When other
bases are used, the formation of β-keto ester intermedi-

















Scheme 1 Synthesis of β-keto esters from ethyl chloroformate and its conversion into pyrazolones.
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ring at r.t. The addition of hydrazine hydrate to the lat-
ter reaction mixtures gave the desired product in low
yield (Table 8), and the corresponding hydrazone of ke-
tones was isolated as the major product. After finding
the suitable base, the reaction conditions were optimized
further by varying the solvents to improve the yield. It
was found that the hydrocarbon solvent (toluene) pro-
duced better yield compared to the cyclic ether solvent
(THF). This may be due to the possible destabilization
of formed intermediate with charge in the case of hy-
drocarbon solvent like toluene, and hence, the formed
enolate reacts with ethyl chloroformate smoothly.
After optimizing the reaction with the suitable base
(LiHMDS) and solvent (toluene), the same conditions
were employed for the synthesis of various β-keto esters
which in turn are converted into their corresponding
pyrazolones 1 to 21 and 23 to 26 in situ by the addition
of either hydrazine or its derivatives to prove the ge-
nerality of the reaction, and the results are tabulated in
Table 8. The reactions have been monitored by thin
layer chromatography (TLC), and the obtained crude
products were purified by column chromatography. The
β-keto esters were efficiently converted into their corre-
sponding pyrazolones with good to excellent yields. All
the synthesized compounds 1 to 21 and 23 to 26 have
been characterized through IR, 1H NMR, 13C NMR and
mass spectral data. The examination of the 1H NMR
spectrum of 26 clearly shows that the formation of
doublet at δ 1.34 ppm with the coupling constant of
6.92 Hz integrating for six protons is due to the two
methyl groups of isopropyl substituent at C3 of pyrazo-
lone moiety. A multiplet between δ 2.79 and 2.49 ppmTable 7 Effect of solvent and base on the yield of 12
Base Ketone (eq.)
LiHMDS (1.0M THF) (1 eq.) 3
LiHMDS (1.0M THF) (2 eq.) 3
KHMDS (3 eq.) 7
NaH (2 eq.) 50
NaOMe (2 eq.) 75
KOtBu (3 eq.) 10
LiHMDS (1.0M THF) (3.5 eq.) 7
aIsolated yield.integrating for one proton is due to the methine proton
of iso-propyl substituent at C3 of pyrazolone moiety.
The singlet at δ 3.33 ppm integrating for one proton is
due to the proton at C4. Two broad singlets that appeared
between δ 9.5 to 9.3 ppm and δ 11.2 to 11.1 ppm integrat-
ing for one proton each are due to -NH and -OH protons,
respectively. This supports the 1H NMR findings that
pyrazolone moiety is in its enol rather than the keto form
since the spectrum was recorded in deuterated DMSO
solvent. Similarly, the examination of the 13C NMR spec-
trum reveals the following points. The two signals that
appeared at aliphatic regions 22.24 and 25.69 ppm are due
to methyl and methine carbon, respectively, of the iso-
propyl substituent at C3 of the pyrazolone moiety. The
signal at 86.22 ppm is due to the C4. The two downfield
signals appeared at 160.75 and 150.39 ppm. The relatively
downfield signal has been assigned as C5, and the rela-
tively upfield has been assigned as C3. The m/z observed
at 126.9 in liquid chromatography-mass spectrometry
(LC-MS) spectrum also supports the formation of com-
pound 26. In the similar way, the chemical shifts of all the
other compounds have been assigned and are included in
the experimental part. Some of the compounds 4, 7, 16,
21, 23 and 24 have been crystallized and subjected to the
single crystal X-ray diffraction studies [68-75] and are
available in the literature (Ortep plots are included in the
Additional file 1); particularly, sample 4 has been crystal-
lized as both in keto form and enol form. All the above
discussions clearly revealed the formation of the desired
products. This method is very simple, fast and applicable
to the ketones having the alkyl halogens, protecting
groups like Boc and Cbz that were tolerated and proved to
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aPercentage of products in crude LC-MS.
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method is successful for different ketones, it can also be
useful for the synthesis of pharmaceutically important
pyrazolones.
We have investigated the newly synthesized pyrazoles
for their antibacterial activity against E. coli (ATTC-
25922), S. aureus (ATTC-25923), P. aeruginosa (ATTC-
27853) and K. pneumonia (recultured) bacterial strains
by the disc diffusion method [57,58]. Results of these
studies were given in Table 1 and compared with the
standard ciprofloxacin. Most of the synthesized com-
pounds exhibited very good bacterial activity; particu-
larly, compounds 7, 13, 14, 23, 25 and 26 have shown
very good inhibition against all the bacterial strains
tested. Compounds 9 to 11, 13, 14, 19, 20 and 26 have
shown a moderate to good inhibition against all the bac-
terial strains. Compounds 8 and 24 have poor bacterialFigure 1 Molecular docking result of compound 14. (a) The docked po
protein is shown in the surface model, and the ligand is shown in the stick
The amino acid residue interaction, hydrogen bond networks in the bindinactivity. The SAR studies on these compounds revealed
that the aliphatic substituents (either cyclic or acyclic)
on the main cage increase their biological activities. On
the other hand, compounds bearing the aromatic sub-
stituents and the fused ring systems decrease their activ-
ity. Halogen substitution in alkyl group also reduces
their activity. Some of the tested compounds are equipo-
tent or more potent than the standards used.
Newly synthesized pyrazoles were screened for their
antifungal activity against A. flavus (NCIM no. 524), A.
fumigates (NCIM no. 902), P. marneffei (recultured) and
T. mentagrophytes (recultured) in DMSO by the serial
plate dilution method [34-36]. Most of the tested com-
pounds exhibited good fungicidal activities; particularly,
compounds 10, 11, 19 and 25 were found to be highly
potent to all the four fungi tested. Compounds 1 to 9,
13 to 15, 17, 20, 21, 23, 25 and 26 were shown to have
good to moderate activity to all the fungi tested.
All the synthesized compounds 1 to 26 have been
subjected to the docking studies against ACHN (human
renal cell carcinoma), Panc-1 (human pancreatic adeno-
carcinoma) and HCT-116 (human colon cancer) and
then subjected to WST-1 cytotoxicity assay. Among the
26 synthesized compounds, compounds 14, 20 and 4 are
found to have least binding energy value and Z score
value. These compounds are more stable ligand-recep-
tor complex amongst other compounds. Compound 14
shows the best binding conformation with nf-κb (total
energy = −91.9971 kcal/mol, Z score = −119). The best
binding mode of compound 14 at the NF-κb binding site
and the residues involved in the interaction, correspon-
ding two-dimensional (2D) interaction models, hydrogen
bonds and bond distance are shown in Figure 1. Com-
pound 14 binds to the binding sites and forms three
hydrogen bonds with NF-κb involved in pancreatic can-
cer. It can be seen in Figure 1 that nitrogen atoms of
compound 14 formed a hydrogen bond with Pro-65 andses of compound 14 at the site of nuclear factor kappa b; target
model. (b) A close-up view of the docked pose of compound 14. (c)
g pocket and the distance (in Angstrom units) of bonds are shown.
Figure 2 Molecular docking result of compound 18. (a) Binding pose of compound 18 in the vascular endothelial growth factor receptor-2.
(b) A close-up view of the binding pose of compound 18; protein structure is shown in the surface model, and the ligand is shown in the stick
model. (c) H bond networks with protein residues are shown.
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http://www.orgmedchemlett.com/content/3/1/6Val115. In addition, Arg59 has one H bond with the
bond distance of 3.91 Å. The binding pose and inter-
action mode of compound 14 are shown in Figure 1.
The post-docking analysis of compound 18 has shown
higher affinity with VGFR2 which has key role in renal
cancer development (total energy = −104.9856 kcal/mol,
Z score = −125.5). Compound 18 binds to the VGFR2
and forms one H bond interaction with Arg118 and
Phe115 residues. The best binding pose of compound 18
in the VGFR2 and corresponding 2D interaction mo-
dels, hydrogen bonds and bond distance are depicted in
Figure 2. Docking analysis of compound 1 has shown the
best conformation with PI3K (total energy = −119.541
kcal/mol, Z score = −125.5). The binding affinity of com-
pound 1 towards PI3K is investigated in detail. On analysis
of the interaction and position of compound 1 in the PI3K
binding site, it is observed that five H bonds are found,
and the amino acid residues Asp654, Gln846, ARG649
and Trp201 participated in the interaction. TheFigure 3 Molecular docking result of compound 1. (a) Docked poses o
close-up view of the docked pose of compound 1; protein structure is sho
(color by atom). (c) H bond networks and bond distance are shown.surface of PI3K with compound 1 along with the
main contact residues of PI3K is labelled, and hydro-
gen bond distances are shown in Figure 3.
In continuation of the docking analysis, the com-
pounds 1 to 26 have been subjected to the cyctotoxicity
studies. Towards this, a panel of three cancer cells
representing multiple cancers of clinical relevance were
obtained from ATCC, namely ACHN (human renal cell
carcinoma), Panc-1 (human pancreatic adenocarcinoma)
and HCT-116 (human colon cancer). Cells were main-
tained in DMEM containing 10% heat-inactivated fetal
bovine serum and kept in humidified 5% CO2 incubator
at 37°C. Logarithmically growing cells were plated at a
density of 5 × 103 cells/well in a 96-well tissue culture
grade micro-plate and allowed to recover overnight. The
cells were challenged with varying concentration of com-
pounds for 48 h. Control cells received standard media
containing dimethylsulfoxide vehicle at a concentration
of 0.2%. After 48 h of incubation, cell toxicity wasf compound 1 in human phosphoinositide 3-kinase binding site. (b) A
wn in the surface model, and the ligand is shown in the stick model
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Technologies, Inc.); (WST-1 [2-(2-methoxy-4-nitrophe-
nyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)]-2H-tetrazo-
lium, monosodium salt assay). In accordance with the
manufacturer's instructions [36], 5 μL/well CCK-8 rea-
gent was added, and plates were incubated for 2 h.
Cytotoxicity of all the compounds have been determined
by measuring the absorbance on Tecan Sapphire multi-
fluorescence micro-plate reader (Tecan GmbH, Germany)
at a wavelength of 450 nm corrected to 650 nm and nor-
malized to controls. Each independent experiment was
performed thrice and tabulated in Table 6. The compound
18 was found to be inhibitive against only ACHN (human
renal cell carcinoma) cell lines. The compounds 1 and 10
were found to be inhibitive against HCT-116 (human
colon cancer) cell lines. The compound 14 was found to
be inhibitive against Panc-1 (human pancreatic adenocar-
cinoma) as well as HCT-116 (human colon cancer) cell
lines. The docking poses of the compounds 1, 10, 14 and
18 reveals that these molecules are having either more or
strong hydrogen bonding interactions with the target mol-
ecules which may be due to the presence of either O-alkyl
or O-aryl or cyanide groups in it, and hence, these mole-
cules are found to have better activity.Experimental
General
All the NMR spectra were recorded using Bruker AMX
400 or Bruker DPX 300 instrument (Billerica, MA, USA)
with 5-mm PABBO BB-1H tubes. 1H NMR spectra were
recorded using approximately 0.03 M solutions in
d6-DMSO at 300 or 400 MHz with tetramethylsilane
(TMS) as internal reference. 13C NMR spectra were
recorded using approximately 0.05 M solutions in d6-
DMSO at 75 or 100 MHz with TMS as internal refer-
ence. In many cases, pyrazolones were recorded in the
enol form, whenever d6-DMSO was used as solvent.
Melting points were determined by Buchi B-545 appar-
atus (Golden Valley, MN, USA). LC-MS were obtained
using Agilent 1200 series LC (Santa Clara, CA, USA)
and MicromasszQ spectrometer (Manchester, UK).
All reagents were purchased from Sigma-Aldrich
(St. Louis, MO, USA) and used as received. LiHMDS
solutions were kept under nitrogen atmosphere after
opening. Dry toluene, AcOH and EtOH were supplied
by Spectrochem (Mumbai, India). All chemistry was
performed under a nitrogen atmosphere using standard
techniques. The chromatographic separations were per-
formed over silica gel (230 to 400 mesh) using mixtures
of EtOAc and methanol or EtOAc and hexane as eluent.
Solvents were removed under reduced pressure on a
rotovap. Organic extracts were dried with anhydrous
Na2SO4. Visualization of spots on TLC plates waseffected by UV illumination, exposure to iodine vapor
and heating the plates dipped in KMnO4 stain.
General procedure to synthesize pyrazolones from
ketones
LiHMDS (1.0 M solution in toluene, 11 mmol) was
added quickly to a solution of ketone (10 mmol in tolu-
ene (15 mL) using a syringe at 0°C under stirring and
stirred at this temperature for 10 min; then, ethyl
chloroformate (11 mmol) was added quickly. Reaction
mixture was slowly (10 min) brought to room tempe-
rature and stirred for 10 min; then, 2 mL of acetic acid,
15 mL of ethanol and hydrazine hydrate (30 mmol) were
added and refluxed for 15 min. Reaction mixture was
concentrated to dryness under reduced pressure and re-
dissolved in ethyl acetate, the organic layer was washed
with saturated brine solution, dried over Na2SO4 and
evaporated under reduced pressure. Crude product was
purified by recrystallisation using ethanol.
3-(4-Methoxyphenyl)-1H-pyrazol-5(4H)-one (1)
Purified by recrystallisation using ethanol (white solid),
m.p: 221.0°C to 222.3°C, 1H NMR (400 MHz, d6-DMSO)
δH: 3.76 (s, 3H, methyl protons of -OCH3), 5.77 (s, 1H,
proton at C-4), 6.95 (d, J = 8.80 Hz, 2 Hz, 2H, aryl pro-
tons), 7.57 (dd, J = 6.88 Hz and 1.92 Hz, 2H, aryl pro-
tons), 9.70 (bs, 1H, -NH proton), 11.90 (bs, 1H, -OH
proton); 13C NMR (100 MHz, d6-DMSO): δ 55.19 (car-
bon at -OCH3), 86.26 (C-3), 114.20, 123.15, 126.17,
143.09 (aryl carbons), 158.94 (C-4), 161.21 (C-5). MS
calculated for C10H10N2O2: 190.19. Found: 189.0 (M-1).
3-(4-Chlorophenyl)-1H-pyrazol-5(4H)-one (2)
Purified by recrystallisation using ethanol (white solid),
m.p: 243.5°C to 245.0°C, 1H NMR (400 MHz, d6-DMSO)
δH: 5.93 (s, 1H, proton at C-4), 7.46 (d, J = 6.80 Hz, 2H,
aryl protons), 7.69 (d, J = 8.40 Hz, 2H, aryl protons),
9.70 (bs, 1H, -NH proton), 12.15 (bs, 1H, -OH proton);
13C NMR (100 MHz, d6-DMSO): δ 86.82 (C-4), 126.44,
128.78, 132.10 (aryl carbons), 142.0 (C-3), 160.70 (C-5).
MS calculated for C9H7ClN2O: 194.61. Found: 195.0
(M + 1 for Cl35) and 197.0 (M + 3 for Cl37).
3-(4-Fluorophenyl)-1H-pyrazol-5-(4H)-one (3)
Purified by recrystallisation using ethanol (white solid),
m.p: 240.0°C to 241.5°C, 1H NMR (400 MHz, d6-DMSO)
δH: 5.86 (s, 1H, proton at C-4), 7.23 (t, J = 8.72 Hz, 2H,
aryl protons), 7.69 (dd, J = 8.30 and 7.23 Hz, 2H, aryl
protons), 9.70 (bs, 1H, -NH proton), 12.00 (bs, 1H, -OH
proton); 13C NMR (100 MHz, d6-DMSO): δ 86.71 (C-4),
115.52, 115.74, 126.82, 126.74 (aryl carbons), 160.41
(C-4), 162.84 (C-5). MS calculated for C9H7FN2O:
178.10. Found: 177.0 (M-1).
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Purified by recrystallisation using ethanol (white solid),
m.p: 218.5°C to 220.0°C, 1H NMR (400 MHz, d6-DMSO)
δH: 1.99 (s, 3H, methyl protons at C-4), 7.34 (t, J = 7.20
Hz, 1H, para proton of aryl), 7.45 (t, J = 8.00 Hz, 2H,
meta protons of aryl), 7.53 (d, J = 8.00 Hz, 2H, ortho
protons of aryl), 9.50 (bs, 1H, -NH proton), 11.70 (bs,
1H, -OH proton); 13C NMR (100 MHz, d6-DMSO): δ
7.66 (methyl carbon at C-4), 95.98 (C-4), 126.31, 127.49,
128.78, 131.15 (aryl carbons), 139.54 (C-3), 160.28
(C-5). MS calculated for C10H10N2O: 174.19. Found:
173.0 (M-1).
4,5,6,7-Tetrahydro-2H-indazol-3(3aH)-one (5)
Purified by recrystallisation using ethanol (white solid),
m.p: 286.0°C to 288.0°C, 1H NMR (400 MHz, d6-DMSO)
δH: 1.66 to 1.59 (m, 4H, four protons of cyclohexane
fused ring), 2.21 (t, J = 5.20 Hz, 2H, two protons of
cyclohexane fused ring), 2.42 (t, J = 6.0 Hz, 2H, two pro-
tons of cyclohexane fused ring), 9.95 (bs, 2H); 13C NMR
(100 MHz, d6-DMSO): δ 19.35, 21.73, 22.74, 23.32 (car-
bons of fused cyclohexane part), 98.88 (C-3 of pyrazole
ring), 140.19 (C-4 of pyrazole ring), 158.87 (C-5 of
pyrazole ring). MS calculated for C7H10N2O: 138.08.
Found: 138.16 (M+).
3a,4,5,6,7,8-Hexahydrocyclohepta(e)pyrazol-3-(2H)-one (6)
Purified by recrystallisation using ethanol (white solid),
m.p: 220.5°C to 221.8°C, 1H NMR (400 MHz, d6-DMSO)
δH: 1.56 to 1.50 (m, 4H, four protons of fused cy-
cloheptane), 1.71 (d, J = 5.52 Hz, 2H, two protons of
fused cycloheptane), 2.29 (t, J = 5.60 Hz, 2H, two pro-
tons of fused cycloheptane), 2.50 (t, J = 3.28 Hz, 2H, two
protons of fused cycloheptane), 9.20 (bs, 1H, -NH pro-
ton), 11.00 (bs, 1H, -OH proton); 13C NMR (100 MHz,
d6-DMSO): δ 23.04, 27.68, 29.36, 32.01 (carbons of fused
cycloheptane ring), 102.81 (C-4) 143.81 (C-3 of pyrazole
ring), 159.25 (C-5). MS calculated for C8H12N2O: 152.19.
Found: 153.0 (M + 1).
4,5,6,7,8,9-Hexahydro-2H-cycloocta(c)pyraol-3(3aH)-one (7)
Purified by recrystallisation using ethanol (white solid),
m.p: 221.6°C to 228.8°C, 1H NMR (400 MHz, d6-DMSO)
δH: 1.40 (m, 4H, protons of fused cyclooctane ring), 1.51
(m, 2H, protons of fused cyclooctane ring), 1.58 (m, 2H,
protons of fused cyclooctane ring), 2.34 (t, J = 6.2 Hz,
2H, protons of fused cyclooctane ring), 2.54 (t, J = 6.2
Hz, 2H, protons of fused cyclooctane ring), 9.03 (bs,
1H, -NH proton), 11.00 (bs, 1H, -OH proton); 13C NMR
(100 MHz, d6-DMSO): δ 20.13, 24.27, 25.50, 25.76,
28.76, 28.94 (carbons of fused cyclooctane ring), 100.42
(C-4), 141.62 (C-3), 159.42 (C-5). MS calculated for
C9H14N2O: 166.20. Found: 167.0 (M + 1).3-Cyclohexyl-1H-pyrazol-5(4H)-one (8)
Purified by recrystallisation using ethanol (white solid),
m.p: 241.5°C to 243.0°C, 1H NMR (400 MHz, d6-DMSO)
δH: 1.21 to 1.26 (m, 1H, proton of cyclohexyl ring), 1.29
to 1.34 (m, 4H, protons of cyclohexyl ring), 1.63 to 1.71
(m, 3H, protons of cyclohexyl ring), 1.84 to 1.90 (m, 2H,
protons of cyclohexyl ring)), 2.44 to 2.50 (m, 1H, proton
at C1′ of cyclohexyl ring), 5.20 (s, 1H, proton at C-4),
9.30 (bs, 1H, -NH proton), 11.00 (bs, 1H, -OH proton);
13C NMR (100 MHz, d6-DMSO) δ: 25.97, 26.08, 32.66,
35.60 (carbons of cyclohexyl ring), 86.74 (C-4), 149.83
(C-3), 161.17 (C-5). MS calculated for C9H14N2O: 166.22.
Found: 166.9 (M+).
3-(3-Chloropropyl)-1H-pyrazol-5(4H)-one (9)
Purified by recrystallisation using ethanol (white solid),
m.p: 155.8°C to 156.5°C, 1H NMR (400 MHz, d6-DMSO)
δH: 2.00 to 1.93 (m, 2H, methylene protons at C2′ of
propyl), 2.57 (t, J = 7.36 Hz, 2H, methylene protons at
C1′ of propyl), 3.62 (t, 6.40 Hz, 2H, methylene protons
at C3′ of propyl), 5.25 (s, 1H), 9.50 (bs, 1H, -NH pro-
ton), 11.20 (bs, 1H, -OH proton); 13C NMR (100 MHz,
d6-DMSO): δ 23.51 (C2′ of propyl), 37.18 (C1′ of propyl),
45.13 (C3′ of propyl), 88.56 (C-4), 143.39 (C-3), 161.20
(C-5). MS calculated for C6H9ClN2O: 160.60. Found:
161.0 (M + 1 for Cl35) and 163.60 (M + 3 for Cl37).
7-Methoxy-4,5-dihydro-2H-benzo(g)indazol-23(3aH)-one (10)
Purified by recrystallisation using ethanol (white solid),
m.p: 116.4°C to 118.2°C, 1H NMR (400 MHz, d6-DMSO)
δH: 2.50 (t, J = 5.50 Hz, 2H, protons of cyclohexyl B
ring), 2.82 (t, J = 5.6 Hz, 2H, protons of cyclohexyl B
ring), 3.75 (s, 3H, protons of methoxy group), 6.80 (d,
J = 7.0 Hz, 1H, aryl proton of C ring), 6.86 (s, 1H, aryl
proton of C ring), 7.43 (d, J = 7.0 Hz, 1H, aryl proton of
C ring), 9.50 (bs, 1H, -NH); 13C NMR (100 MHz, d6-
DMSO): δ 17.91, 30.04, 30.52 (carbons of cyclohexyl
B ring), 55.52 (methoxy carbon), 97.83 (C-4), 112.20,
114.59, 114.81, 120.61, 122.61, 138.18, 139.82, 157.82
(C-3), 158.97 (C-5). MS calculated for C12H12N2O2:
216.23. Found: 215.0 (M-1).
3-(2,3-Dihydrobenzofuran-5-yl)-1H-pyrazol-5(4H)-one (11)
Purified by recrystallisation using ethanol (white solid),
m.p: 237.5°C to 239.0°C, 1H NMR (400 MHz, d6-DMSO)
δH: 3.19 (t, J = 8.70 Hz, 2H, protons of benzofuran ring),
4.54 (t, J = 8.70 Hz, 2H, protons of benzofuran ring),
5.74 (s, 1H, proton at C-4), 6.67 (d, J = 8.28 Hz, 1H, aryl
proton of benzofuran ring), 7.38 (dd, J = 8.28 Hz, 1.82
Hz, 1H, aryl proton of benzofuran ring), 7.51 (s, 1H, aryl
proton of benzofuran ring), 9.65 (bs, 1H, -NH proton),
11.85 (bs, 1H, -OH proton); 13C NMR (100 MHz, d6-
DMSO): δ 28.95 (C of benzofuran), 71.14 (C of ben-
zofuran), 86.16 (C-3), 109.05, 121.84, 123.09, 124.77,
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(carbon of benzofuran), 161.16 (C-5). MS calculated for
C11H10N2O2: 202.20. Found: 203.0 (M + 1).
3-(Biphenyl-4-yl)-1H-pyrazol-5(4H)-one (12)
Purified by recrystallisation using ethanol (white solid),
m.p: 236.5°C to 265.0°C, 1H NMR (400 MHz, d6-DMSO)
δH: 5.94 (s, 1H, proton at C-4), 7.37 (t, J = 7.5 Hz, 1H,
aryl proton), 7.47 (t, J = 7.5 Hz, 2H, aryl protons), 7.76
to 7.69 (m, 6H, aryl protons), 9.77 (bs, 1H, -NH proton),
12.13 (bs, 1H, -OH proton); 13C NMR (100 MHz, d6-
DMSO): δ 86.88 (C-4), 125.26, 126.51, 126.97, 127.54,
128.96 (aryl carbons), 139.25 (C-3), 139.50 (C-5). MS
calculated for C15H10N2O2: 236.26. Found: 235.0 (M-1).
3-(Thiophen-2-yl)-1H-pyrazol-5(4H)-one (13)
Purified by recrystallisation using ethanol (white solid),
m.p: 204.0°C to 205.0°C, 1H NMR (400 MHz, d6-DMSO)
δH: 5.67 (s, 1H, proton at C-4), 7.07 (bs, 1H, proton of
thiophenyl ring), 7.32 (bs, 1H, proton of thiophenyl
ring), 7.42 (bs, 1H, proton of thiophenyl ring), 9.67 (bs,
1H, -NH), 12.05 (bs, 1H, -OH). MS calculated for
C7H6N2OS: 166.20. Found: 167.0 (M + 1).
3-(5-Oxo-4,5-dihydro-1H-pyrazol-3-yl)benzonitrile (14)
Purified by recrystallisation using ethanol (white solid). 1H
NMR (400 MHz, d6-DMSO) δH: 6.02 (s, 1H, proton at C-
4), 7.59 (t, J = 10.4 Hz, 1H, aryl proton), 7.73 (d, J = 10.4
Hz, 1H, aryl proton), 7.99 (d, J = 10.4, 1H, aryl proton),
8.12 (s, 1H, aryl proton), 10.00 (bs, 1H, -NH proton),
12.02 (bs, 1H, -OH proton). MS calculated for C10H7N3O:
185.18. Found: 184.0 (M-1).
Ethyl 3-oxo-2,3,3a,4,6,7-hexahydropyrazolo[4,3-c]pyridine-5-
caboxylate (15)
Purified by recrystallisation using ethanol (white solid),
m.p: 212.5°C to 213. 8°C, 1H NMR (400 MHz, d6-
DMSO) δH: 1.90 (t, J = 7.08 Hz, 3H, methyl of ethyl
group), 2.50 (m, 2H, protons of ring B), 3.56 (t, J = 5.7
Hz, 2H, protons of ring B), 4.04 (q, J = 7.08 Hz, 2H,
methylene of ethyl group), 4.18 (s, 2H, protons of ring
B), 9.80 (bs, 1H, -NH proton), 11.30 (bs, 1H, -OH pro-
ton); 13C NMR (100 MHz, d6-DMSO): δ 14.62 (methyl
carbon of ethyl group), 21.62 (carbon of ring B), 21.92
(methylene carbon of ethyl group), 60.89, 96.06 (C-4 of
pyrazole ring), 138.12, 155.08 (C-3 of pyrazole ring),
156.33 (C-5 of pyrazole ring). MS calculated for
C9H13N3O3: 211.21. Found: 212.0 (M + 1).
Tert-butyl 3-oxo-2,3,3a,4,6,7-hexahydropyrazolo[4,3-c]
pyridine-5-carboxylate (16)
Purified by recrystallisation using ethanol (white solid),
m.p: 225.5°C to 227.5°C, 1H NMR (400 MHz, d6-DMSO)
δH: 1.40 (s, 9H, methyl protons of Boc), 2.49 (t, q = 1.77Hz, 2H, protons of ring B), 3.51 (t, J = 5.72 Hz, 2H, pro-
tons of ring B), 4.13 (s, 2H, protons of ring B); 13C NMR
(100 MHz, d6-DMSO): δ 21.75 (carbons of B ring),
(28.08 methyl carbons of Boc group), 59.77 (carbon of B
ring), 78.94 (quaternary carbon of Boc), 96.21 (C-4 of
pyrazole ring), 138.24 (C-3 carbon of pyrazole ring),
154.19 (C-5 carbon of pyrazole ring), 156.37 (carbonyl
carbon of Boc). MS calculated for C11H17N3O3: 239.27.
Found: 239.8 (M+).
3-(2,5-Dimethylfuran-3-yl)-1H-pyrazol-5(4H)-one (17)
Purified by recrystallisation using ethanol (white solid),
1H NMR (400 MHz, d6-DMSO) δH: 2.21 (s, 3H, methyl
proton of furan ring), 2.32 (s, 3H, methyl proton of furan
ring), 5.51 (s, 1H, proton at C-4) 6.27 (s, 1H, proton of
furan ring), 9.60 (bs, 1H, -NH proton), 11.62 (bs, 1H, -OH
proton). MS calculated for C9H10N2O2: 178.18. Found:
179. 0 (M + 1).
Benzyl 3-oxo-2,3,3a,4,6,7-hexahydropyrazolo[4,3-c]pyridine-
5-carboxylate (18)
Purified by recrystallisation using ethanol (white solid),
m.p: 225.4°C to 226.1°C, 1H NMR (400 MHz, d6-DMSO)
δH: 2.50 to 2.56 (m, 2H, protons of ring B), 3.61 (s, 2H,
protons of ring B), 4.23 (d, J = 10.80 Hz, 2H, protons of
ring B), 5.10 (s, 2H, protons of methylene of Cbz group),
7.38 to 7.30 (m, 5H, aryl protons of Cbz), 9.88 (bs,
1H, -NH proton), 11.16 (bs, 1H, -OH proton); 13C NMR
(100 MHz, d6-DMSO): δ 41.27, 42.77, 66.39 (carbons of
ring B), 86.72 (C-4), 127.69, 127.01, 128.46 (aryl car-
bons), 136.90 (C-3), 157.72 (C-5). MS calculated for
C14H15N3O3: 273.28. Found: 273.8 (M+).
5-Tert-butyl-4,5,6,7-tetrahydro-2H-indazol-3(3aH)-one (19)
Purified by recrystallisation using ethanol (white solid),
m.p: 243.5°C to 244.8°C, 1H NMR (400 MHz, d6-DMSO)
δH: 0.89 (s, 9H, protons of three methyl groups), 1.18 to
1.25 (m, 2H, protons of ring B), 1.85 to 1.92 (m, 2H, pro-
tons of ring B), 2.39 to 2.29 (m, 2H, protons of ring B),
2.55 (m, 1H, proton of ring B); 13C NMR (100 MHz, d6-
DMSO): δ 20.73 (carbons of methyl groups of tertiary
group), 22.54, 24.48, 27.81, 27.85, 32.70, 45.50 (quater-
nary carbon of tertiary group), 99.42 (C-4 of pyrazole
ring), 140.46 (C-3 of pyrazole ring), 158.88 (C-5 of
pyrazole ring). MS calculated for C11H18N2O: 194.21.
Found: 194.8 (M+).
3-(Biphenyl-4-yl)-1-(4-fluorophenyl)-1H-pyrazol-5(4H)-one (20)
Purified by recrystallisation using ethanol (white solid),
m.p: 156.2°C to 157.5°C, 1H NMR (400 MHz, d6-DMSO)
δH: 6.07 (s, 1H at C-4), 7.31 to 7.40 (m, 3H, aryl pro-
tons), 7.48 (t, J = 8.0 Hz, 2H, aryl protons), 7.07 to 7.33
(m, 4H, aryl protons), 7.83 to 7.93 (m, 4H, aryl protons),
11.94 (bs, 1H, -OH proton at C-5); 13C NMR (100 MHz,
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139.91, 140.17 (aryl carbons), 149.69 (C-3), 154.18,
159.05 (aryl carbons), 161.46 (C-5). MS calculated for
C21H15FN2O: 330.55. Found: 329.0 (M-1).
3-Ethyl-4-methyl-1H-pyrazol-5(4H)-one (21)
Purified by recrystallisation using ethanol (white solid),
m.p: 233.4°C to 234.1°C, 1H NMR (400 MHz, d6-DMSO)
δH: 1.07 (t, J = 7.64 Hz, 3H, methyl protons of ethyl
group), 1.72 (s, 3H, methyl at C-4), 2.40 (q, J = 7.6 Hz,
2H, methylene protons of ethyl group), 9.50 (bs, 1H, -OH
proton), 10.05 (bs, 1H, -OH proton); 13C NMR (100 MHz,
d6-DMSO): δ 11.34 (methyl carbon of ethyl group), 18.35
(methyl group at C-4), 22.99 (methylene carbon of ethyl
group), 99.73 (C-4), 147.27 (C-3), 164.86 (C-5). MS calcu-
lated for C6H10N2O: 126.15. Found: 128.0 (M + 2).
4-Ethyl-3-phenyl-1H-pyrazol-5(4H)-one (23)
Purified by recrystallisation using ethanol (white solid),
m.p: 88.3°C to 89.1°C. 1H NMR (400 MHz, d6-DMSO)
δH: 1.15 (t, J = 7.6 Hz, 3H, protons of methyl group),
2.64 (q, J = 7.6 Hz, 2H, protons of methylene group),
7.17 to 7.13 (m, 1H), 7.41 to 7.32 (m, 3H), 10.00 (bs,
2H, -OH and -NH protons); 13C NMR (100 MHz, d6-
DMSO): δ 13.57 (methyl carbon of ethyl group), 19.10
(methylene carbon of ethyl group), 102.27 (C-4), 125.34
(ipso), 128.12 (ortho), 128.60 (meta), 133.88 (para),
142.49 (C-3), 159.20 (C-5). MS calculated for C11H12N2O:
188.22. Found: 188.8 (M+).
3-Cyclohexyl-4-methyl-1H-pyrazol-5(4H)-one (24)
Purified by recrystallisation using ethanol (white solid),
m.p: 205.4°C to 206.2°C. 1H NMR (400 MHz, d6-DMSO)
δH: 1.25 to 1.28 (m, 1H, proton of cyclohexyl ring) 1.32
to 1.40 (m, 4H, protons of cyclohexyl ring), 1.66 to 1.76
(m, 8H, 5 protons of cyclohexyl ring and protons of me-
thyl group), 2.40 to 2.50 (m, 1H, proton of cyclohexyl
ring), 9.50 (bs, 1H, -NH proton) 10.52 (bs, 1H, -OH
proton); 13C NMR (100 MHz, d6-DMSO): δ 6.91 (car-
bon of methyl group), 26.01, 26.53, 31.91, 36.42 (car-
bons of cyclohexyl ring), 94.38 (C-4), 145.71 (C-3),
160.12 (C-5). MS calculated for C10H16N2O2: 180.24.
Found: 180.8 (M+).
3-Cyclopropyl-1H-pyrazol-5(4H)-one (25)
Purified by recrystallisation using ethanol, m.p: 215.5°C to
216.8°C (white solid).1H NMR (400 MHz, d6-DMSO) δH:
0.58 to 0.55 (m, 2H, protons of cyclopropyl), 0.85 to 0.81
(m, 2H, protons of cyclopropyl), 1.75 to 1.68 (m, 1H, pro-
ton of cyclopropyl), 9.50 (bs, 1H, -NH proton), 11.52 (bs,
1H, -OH proton); 13C NMR (100 MHz, d6-DMSO): δ 7.27
(C-1′ of cyclopropyl ring), 7.59 (C-2′, 3′ of cyclopropylring), 85.78 (C-4), 146.75 (C-3), 160.78 (C-5). MS calcu-
lated for C6H8N2O: 124.14. Found: 124.9 (M+).
3-Isopropyl-1H-pyrazol-5(4H)-one (26)
Purified by recrystallisation using ethanol, m.p: 198.2°C
to 199.4°C (white solid).1H NMR (400 MHz, d6-DMSO)
δH: 1.13 (d, J = 6.92 Hz, 6H), 2.79 to 2.72 (m, 1H), 5.20
(s, 1H), 9.32 (bs, 1H, -NH proton), 11.50 (bs, 1H, -OH
proton); 13C NMR (100 MHz, d6-DMSO): δ 22.24 (car-
bon of two CH3 of iso-propyl), 25.69 (methine carbon of
iso-propyl), 86.22 (C-4), 150.39 (C-3), 160.75 (C-5). MS
calculated for C6H10N2O: 126.15. Found: 126.9 (M+).
Conclusions
The β-keto esters from ethyl chloroformate was success-
fully attempted, and the developed method is simple, fast
and applicable to the ketones having the alkyl halogens,
protecting groups like Boc and Cbz that were tolerated
and proved to be useful in the synthesis of fused bicyclic
and tricyclic pyrazolones efficiently using cyclic ketones.
Since this method is successful for different ketones, it
can be useful for the synthesis of pharmaceutically im-
portant pyrazolones also. All the new pyrazolones were
subjected to antimicrobial, docking and cytotoxicity
assay against ACHN (human renal cell carcinoma),
Panc-1 (human pancreatic adenocarcinoma) and HCT-
116 (human colon cancer) cell line. Most of them were
found to be active against different bacterial and fungal
strains tested, and some of them were found to have
promising activity. The in silico and cytotoxicity studies
reveal that compound 18 was found to be inhibitive
against only ACHN (human renal cell carcinoma) cell
lines. The compounds 1 and 10 were found to be inhibi-
tive against HCT-116 (human colon cancer) cell lines.
The compound 14 was found to be inhibitive against
Panc-1 (human pancreatic adenocarcinoma) as well as
HCT-116 (human colon cancer) cell lines, and hence,
further investigations are in need in these promising lead
molecules.
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